4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Keros Therapeutics, Inc. (KROS) operates in the Biotechnology industry and is headquartered in Lexington, United States with about 87 employees. Its market capitalization is roughly $232 million. In the fiscal year ended 2025-12-31, KROS reported $244M in revenue and $87M in net income.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Interactive charts & full statements → Open the KROS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $244M | $4M | $0M | $0M | — |
| Operating Income (EBIT) | $68M | ($210M) | ($168M) | ($108M) | — |
| Net Income | $87M | ($187M) | ($153M) | ($105M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $14M | $18M | $211M |
| Operating Income (EBIT) | ($26M) | ($29M) | ($15M) | ($40M) | $152M |
| Net Income | ($24M) | ($24M) | ($7M) | ($31M) | $148M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $338M | $616M | $370M | $307M | — |
| Total Liabilities | $35M | $44M | $38M | $29M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KROS viewer.
About TickerBase · Data methodology & sources